BACKGROUND Hepatocellular carcinoma (HCC) is the fifth most prevalent malignant tumor in China after lung cancer, gastric cancer, esophageal cancer, and breast cancer, and has a high mortality rate. Though there are a series of therapeutic strategies is now available for HCC in clinical practice,
Three new 9,19-cycloartane triterpene glycosides, asiaticoside A (1), asiaticoside B (2), and 25-O-ethylcimigenol-3-O-beta-D-xylopyranoside (3), together with cimiacemoside I (4), 25-O-acetylcimigenol-3-beta-O-D-xyloside (5), and 25-anhydrocimigenol-beta-O-D-xyloside (6) were isolated from the